Increased concentrations of soluble CD40 ligand platelet in patients with primary antiphospholipidic syndrome;Incremento en las concentraciones de ligando CD40 soluble plaquetario en pacientes con síndrome antifosfolipídico primario

Reumatologia Clinica

Volumn 9, Issue 4, 2013, Pages 216-220

  Galicia López, Aida ^a   Olguín Ortega, Lourdes ^a   Saavedra, Miguel A ^a   Méndez Cruz, René ^b   Jimenez Flores, Rafael ^b   García de la Peña, Maximiliano ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Antiphospholipids antibodies; Atherosclerosis; Platelet activation; Soluble CD40 ligand; Thrombosis

Indexed keywords

CD40 LIGAND;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PREGNANCY; THROMBOSIS;

ACTIVACIÓN PLAQUETARIA; ANTICUERPOS ANTIFOSFOLIPÍDICOS; ANTIPHOSPHOLIPIDS ANTIBODIES; ATEROSCLEROSIS; ATHEROSCLEROSIS; LIGANDO CD40 SOLUBLE; PLATELET ACTIVATION; SOLUBLE CD40 LIGAND; THROMBOSIS; TROMBOSIS;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BLOOD PLATELETS; CD40 LIGAND; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; THROMBOSIS;

EID: 84879852598     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2012.10.018     Document Type: Article

References (25)

1. Hughes G., Harris E.N., Gharavi A. The anticardiolipin syndrome. J Rheumatol 1986, 13:486-489.
2. López-Pedrera C., Buendía P., Aguirre M.A., Velasco F., Cuadrado M.J. Antiphospholipid syndrome and tissue factor: A thrombotic couple. Lupus 2006, 15:161-166.
3. Cuadrado M.J., López-Pedrera C., Khamashta M.A., Camps M.T., Tinahones F., Torres A., et al. Thrombosis in primary antiphospholipid syndrome. A pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997, 40:834-841.
4. Salmon J.E., de Groot P.G. Pathogenic role of antiphospholipid antibodies. Lupus 2008, 17:405-411.
5. Jy W., Tiede M., Bidot C.J., Horstman L.L., Jimenez J.J., Chirinos J., et al. Platelet activation rather than endothelial injury indentifies risk of thrombosis in subject positive for antiphospholipid antibodies. Thromb Res 2007, 121:319-325.
6. Jara L.J., Medina G., Vera-Lastra O. Systemic antiphospholipid syndrome and atherosclerosis. Clin Rev Allergy Immunol 2007, 32:172-177.
7. López D., Garcia-Valladares I., Palafox-Sanchez C.A., De La Torre I.G., Kobayashi K., Matsuura E. Oxidized low-density lipoprotein/β2 glycoprotein I complexes and autoantibodies to OxLig-1/β2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am J Clin Pathol 2004, 121:426-436.
8. Margarita A., Batuca J., Scenna G., Alves J.D., López L., Iannaccone L., et al. Subclinical atherosclerosis in primary antiphospholipid syndrome. Ann NY Acad Sci 2007, 1108:475-480.
9. Schönbeck U., Libby P. CD40 signaling and plaque instability. Circ Res 2001, 89:1092-1103.
10. Schönbeck U., Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001, 58:4-43.
11. Bruemmer D., Riggers U., Holzmeister J., Grill M., Lippek F., Settmacher U., et al. Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesions. Am J Cardiol 2001, 87:21-27.
12. Melter M., Reinders M.E., Sho M., Pal S., Geehan C., Denton M.D., et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 2000, 96:3801-3808.
13. Match F., Schönbeck U., Bonnefoy J.Y., Pober J.S., Libby P. Activation of monocyte-macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysina and tissue factor. Circulation 1997, 96:396-399.
14. Schönbeck U., Mach F., Bonnefoy J.Y., Loppnow H., Flad H.D., Libby P. Ligation of CD40 activates interleukin 1β-coonverting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1β. J Biol Chem 1997, 272:19569-19574.
15. Heeschen C., Dimmoler S., Hamm C.W., van den Brand M.J., Boersma E., Zeithar A.M., et al. Soluble CD40 ligand in acute coronary syndromes. N Eng J Med 2003, 348:1104-1111.
16. Schönbeck U., Varo N., Libby P., Buring J., Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation 2001, 104:2266-2268.
17. Türkey S., Güneri S., Akdeniz B., Ozcan M.A., Baris N., Badak O., et al. Usefulness of preprocedural soluble CD40 ligand for predicting reestenosis after percutaneus coronary intervention in patients with stable coronary artery disease. Am J Cardiol 2006, 97:198-202.
18. Aleksandrova E.N., Novikov A.A., Popkova T.V., Reshetniak T.M., Novikova D.S., Kliukvina N.G., et al. Soluble CD40 ligand in systemic lupus erythematosus and antiphospholipid syndrome. Ter Arkh 2006, 78:35-39.
19. Medina G., Gutiérrez-Moreno A.L., Vera-Lastra O., Saavedra M.A., Jara L.J. Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev 2011, 10:214-217.
20. Matsuura E., Hughes G.R., Khamashta M.A. Oxidation of LDL and its clinical implication. Autoimmun Rev 2008, 7:558-566.
21. Pengo V., Bison E., Ruffatti A., Iliceto S. Antibodies to oxidized LDL/B2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism. Thromb Res 2008, 122:556-559.
22. Ames P.R., Margarita A., Alves J.D. Antiphospholipid antibodies and atherosclerosis: Insights from lupus erythematosus and primary antiphospholipid syndrome. Clin Rev Allergy Immunol 2009, 37:29-35.
23. Gresele P., Migliacci R., Vedovati M.C., Ruffati A., Becattini C., Facco M., et al. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res 2009, 123:444-451.
24. Rand J.H., Wu X.X., Quinn A.S., Taatjes D.J. The Annexin A5-mediated pathogenic mechanisms in the antiphospholipid syndrome: Role in pregnancy losses,thrombosis. Lupus 2010, 19:460-469.
25. Praprotnik S., Ferluga D., Vizjak A., Hvala A., Avcin T., Rozman B. Microthrombotic/microangiopathic manifestations of antiphospholipids syndrome. Clin Rev Allergy Immunol 2009, 36:109-125.